Cholesterol drug showdown: which version works best?

NCT ID NCT07422285

Ongoing Knowledge-focused Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study compares two forms of the cholesterol-lowering drug evolocumab in 400 healthy adults aged 18 to 60. Participants receive a single injection of one version, and researchers measure how much drug gets into the blood and how long it stays. The goal is to see if the two versions are absorbed similarly, not to treat any disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: evolocumab (a cholesterol-lowering drug)
What this could lead to: If successful, this study could help confirm that two manufacturing versions of evolocumab are absorbed similarly, supporting future supply flexibility.
What could go wrong: This is an early-phase trial in healthy people, not patients. It measures drug levels in the blood, not health outcomes, so results may not predict real-world effectiveness or safety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY PARTICIPANTS PHARMACOKINETICS

Contacts and locations

Locations

Fortrea Clinical Research Unit - Dallas

Dallas, Texas, 75247, United States
Fortrea Clinical Research Unit - Daytona Beach

Daytona Beach, Florida, 32117-5116, United States
Fortrea Clinical Research Unit Inc. - Madison

Madison, Wisconsin, 53704-2526, United States
Ohio Clinical Trials, Inc.

Columbus, Ohio, 43212, United States
QPS Bio-Kinetic

Springfield, Missouri, 65802-4842, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.